Inari Medical — Merger or Acquisition (November 2023)
13 slides from Inari Medical's merger presentation, Nov 2, 2023
Slide 1: Inari Medical Investor Update November 2023
Cindy LimFlow Patient Inari Medical Investor Update November 2023 Exhibit 99.2
Slide 2: Forward-Looking Statements
This presentation (together with any other statements or information that we may make in connection therewith) may contain are forward-looking statements. All statements other than statements of historical fact could be deemed forward-looking, including anticipated closing of the LimFlow Acquisition
Slide 3: Today's Announcements
Today’s Announcements 1 2 Our markets and business continue to demonstrate strong growth Continues our mission of offering differentiated solutions for large, underpenetrated markets with a significant unmet need Announced Strong Third Quarter Financial Results Announced Acquisition of LimFlow, a Co
Slide 4: Overview of Inari's Third Quarter Financial Results
Overview of Inari’s Third Quarter Financial Results Inari’s Third Quarter Financial Highlights Key Highlights $490M – $493M 2023 Revenue 28% – 29% Increase Over 2022 2023 Guidance Robust procedure volume growth across our VTE business Meaningful contributions from new product launches and internatio
Slide 5: LimFlow Strongly Aligns with Our Core Mission
cx Strongly Aligns with Our Core Mission Expands TAM and Enhances Long-Term Financial Profile Leverages Our Core Competencies Separate But Complementary Commercial Activities Serves patients first Addresses major unmet clinical needs No incrementalism Adds an attractive ~$1.5B initial US TAM with up
Slide 6: What is CLTI?
What is CLTI? 150k ischemia-related amputations annually in the US2 Following a Major Amputation: Impact of the Disease CLTI is a Global Healthcare Crisis with a Significant and Growing Unmet Clinical Need 10% Die Before Discharge3 Up to 60% Die at One Year4 Up to $800k In Direct Costs / Patient5 Ap
Slide 7: Purpose-Built Technology Designed to Transform the Treatment of CLTI
Purpose-Built Technology Designed to Transform the Treatment of CLTI LimFlow Technology Overview LimFlow’s Transcatheter Arterialization of Deep Veins System (“LimFlow’s System”) How Does LimFlow’s System Work? 1 Bypasses unreconstructible arteries 2 Transforms healthy vein into artery to perfuse lo
Slide 8: Robust Clinical Evidence with Publication in the World's Leading Medical Journal
Robust Clinical Evidence with Publication in the World’s Leading Medical Journal1 PROMISE II Clinical Trial Overview A Landmark Peripheral Artery Disease Study Trial Enrollment 105 Patients 20 US Sites Primary Endpoint Amputation Free Survival at 6 Months (Pre-Specified Literature-Based Goal of 54%)
Slide 9: Large Addressable Market with Potential for Meaningful Expansion
Large Addressable Market with Potential for Meaningful Expansion Nehler et al., Journal of Vascular Surgery, 2014 estimate on 0.35% of population over 40. Management estimate for serviceable number of R5 and R6 patients based on epidemiology literature, independent market research and recent publica
Slide 10: LimFlow is a Highly Attractive Asset in a Market with High Barriers to Entry
Highly innovative, purpose-built, full toolkit system designed specifically to treat no-option CLTI patients On the cusp of US launch (sales reps hired, fully trained and beginning to sell) with ability to efficiently drive adoption (high procedure volume concentration among top accounts) Strong bas
Slide 11: Transaction Summary & Financial Highlights
Transaction Summary & Financial Highlights Key Deal Terms Upfront payment of $250 million in cash at closing Contingent consideration of up to $165 million, subject to the achievement of certain commercial and reimbursement milestones Earliest potential milestone payment would be due in 2025 Financi
Slide 12: Appendix
9 Appendix
Slide 13: Acronym Guide
Acronym Guide CLTI: Chronic Limb-Threatening Ischemia CVD: Chronic Venous Disease PAD: Peripheral Artery Disease VTE: Venous Thromboembolism
Inari Medical — Merger or Acquisition (November 2023) on 6ix